RTI Surgical® Partners in New Manufacturing USA Institute
June 02 2017 - 11:00AM
Business Wire
The Advanced Regenerative Manufacturing
Institute (ARMI) will receive nearly $300 million in public-private
investment from leading manufacturers, universities, nonprofit
organizations and the federal government to develop scalable
manufacturing processes for engineered tissues and organs
RTI Surgical (RTI) (Nasdaq: RTIX), a global surgical implant
company, is part of a new public-private Manufacturing USA
initiative, the Advanced Regenerative Manufacturing Institute
(ARMI). Headquartered in Manchester, New Hampshire, ARMI is the
twelfth Manufacturing USA institute. It brings together a
consortium of nearly 100 partner organizations from industry,
government, academia and the non-profit sector to develop
next-generation manufacturing processes and technologies for cells,
tissues and organs.
Approximately $80 million from the federal government will be
combined with more than $200 million in cost share to support the
development of tissue and organ manufacturing capabilities. As part
of continuing efforts to help revitalize American manufacturing and
incentivize companies to invest in new technology development in
the United States, ARMI will lead the Advanced Tissue
Biofabrication (ATB) Manufacturing USA Institute on behalf of the
Department of Defense.
Under the umbrella of Manufacturing USA, a public-private
network that invests in the development of world-leading advanced
manufacturing technologies, ARMI will work to integrate and
organize the fragmented collection of industry practices and
domestic capabilities in tissue biofabrication technology in order
to better position the US relative to global competition. ARMI will
also focus on accelerating regenerative tissue research and
creating state-of-the-art manufacturing innovations in biomaterial
and cell processing for critical Department of Defense and civilian
needs.
“We need to develop twenty-first century tools for engineered
tissue manufacturing that will allow these innovations to be widely
available – similar to how a fifteenth century tool (the printing
press) allowed knowledge to spread widely during the Renaissance,”
said inventor Dean Kamen, ARMI’s chairman.
ARMI’s efforts are supported by forty-seven industrial partners,
twenty-six academic and academically affiliated partners, and
fourteen government and nonprofit partners. The ARMI partnership
continues to grow.
“RTI Surgical is pleased to participate in the ARMI consortium,”
said Todd Goede, Global Vice President of Research and Development.
“We look forward to providing the regenerative manufacturing
resources and knowledge that we use every day to help patients –
undoubtedly, the lives of many will benefit from the innovations
this initiative will create.”
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company
providing surgeons with safe biologic, metal and synthetic
implants. Committed to delivering a higher standard, RTI’s implants
are used in sports medicine, general surgery, spine, orthopedic,
trauma and cardiothoracic procedures and are distributed in nearly
50 countries. RTI is headquartered in Alachua, Fla., and has four
manufacturing facilities throughout the U.S. and Europe. RTI
is accredited in the U.S. by the American Association of Tissue
Banks and is a member of AdvaMed. For more information, please
visit www.rtix.com.
Forward Looking Statement
This communication contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are based on management’s
current expectations, estimates and projections about our industry,
our management's beliefs and certain assumptions made by our
management. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates," variations of such words
and similar expressions are intended to identify such
forward-looking statements. In addition, except for historical
information, any statements made in this communication about
anticipated financial results, growth rates, new product
introductions, future operational improvements and results or
regulatory actions or approvals or changes to agreements with
distributors also are forward-looking statements. These statements
are not guarantees of future performance and are subject to risks
and uncertainties, including the risks described in public filings
with the U.S. Securities and Exchange Commission (SEC). Our actual
results may differ materially from the anticipated results
reflected in these forward-looking statements. Copies of the
company's SEC filings may be obtained by contacting the company or
the SEC or by visiting RTI's website at www.rtix.com or the SEC's
website at www.sec.gov.
About ARMI
The Advanced Regenerative Manufacturing Institute (ARMI),
headquartered in Manchester, NH, is the 12th Manufacturing USA
Institute. It brings together a consortium of nearly 100 partners
from across industry, government, academia and the non-profit
sector to develop next-generation manufacturing processes and
technologies for cells, tissues and organs. ARMI will work to
organize the current fragmented domestic capabilities in tissue
biofabrication technology to better position the U.S. relative to
global competition. For more information on ARMI, please visit
www.ARMIUSA.org.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170602005079/en/
RTI SurgicalRoxane Wergin, Phone: 386-418-8888Director,
Corporate Communicationsrwergin@rtix.com
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Apr 2023 to Apr 2024